Day One Biopharmaceuticals (NASDAQ:DAWN) Hits New 52-Week High at $17.87

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $17.87 and last traded at $17.79, with a volume of 457624 shares traded. The stock had previously closed at $17.10.

Wall Street Analysts Forecast Growth

DAWN has been the topic of a number of analyst reports. The Goldman Sachs Group decreased their target price on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a "buy" rating on the stock in a research report on Tuesday, February 27th. Oppenheimer reiterated a "market perform" rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. Needham & Company LLC increased their price target on shares of Day One Biopharmaceuticals from $30.00 to $33.00 and gave the stock a "buy" rating in a research report on Wednesday, April 24th. Wedbush reiterated an "outperform" rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, April 24th. Finally, Piper Sandler reiterated an "overweight" rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, Day One Biopharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $39.33.

Day One Biopharmaceuticals Price Performance

The stock has a market cap of $1.55 billion, a price-to-earnings ratio of -7.43 and a beta of -1.48. The business's 50-day simple moving average is $15.29 and its two-hundred day simple moving average is $13.93.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last issued its earnings results on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.07). Equities research analysts forecast that Day One Biopharmaceuticals, Inc. will post -2.67 earnings per share for the current year.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, General Counsel Adam Dubow sold 3,242 shares of the firm's stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $49,440.50. Following the sale, the general counsel now owns 16,585 shares in the company, valued at $252,921.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Samuel C. Blackman sold 2,258 shares of the firm's stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $34,434.50. Following the completion of the transaction, the insider now owns 1,244,662 shares of the company's stock, valued at $18,981,095.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel Adam Dubow sold 3,242 shares of the firm's stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $49,440.50. Following the transaction, the general counsel now directly owns 16,585 shares of the company's stock, valued at approximately $252,921.25. The disclosure for this sale can be found here. Insiders have sold 55,781 shares of company stock worth $883,160 over the last quarter. Corporate insiders own 8.40% of the company's stock.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Several large investors have recently modified their holdings of DAWN. Vanguard Group Inc. raised its stake in Day One Biopharmaceuticals by 8.1% during the third quarter. Vanguard Group Inc. now owns 4,629,754 shares of the company's stock worth $56,807,000 after buying an additional 346,090 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Day One Biopharmaceuticals by 38.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 447,138 shares of the company's stock worth $5,486,000 after buying an additional 125,050 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Day One Biopharmaceuticals by 22.4% during the third quarter. Bank of New York Mellon Corp now owns 220,296 shares of the company's stock worth $2,703,000 after buying an additional 40,387 shares during the last quarter. TimesSquare Capital Management LLC increased its stake in Day One Biopharmaceuticals by 41.8% in the third quarter. TimesSquare Capital Management LLC now owns 1,142,610 shares of the company's stock valued at $14,020,000 after purchasing an additional 336,910 shares in the last quarter. Finally, Deutsche Bank AG increased its stake in Day One Biopharmaceuticals by 5.5% in the third quarter. Deutsche Bank AG now owns 177,137 shares of the company's stock valued at $2,173,000 after purchasing an additional 9,219 shares in the last quarter. Institutional investors own 87.95% of the company's stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.